Repligen
Repligen Corporation, a leading player in the bioprocessing industry, is headquartered in the United States. Founded in 1981, the company has established itself as a key provider of innovative solutions for the development and manufacture of biologics. With a strong presence in major operational regions including Europe and Asia, Repligen focuses on areas such as protein purification, cell culture, and bioprocessing technologies. The company’s core products, including its unique chromatography resins and single-use systems, are designed to enhance efficiency and productivity in biomanufacturing. Repligen's commitment to quality and innovation has positioned it as a trusted partner for biopharmaceutical companies worldwide. Notable achievements include significant growth through strategic acquisitions, solidifying its market position as a frontrunner in bioprocessing solutions.
DitchCarbon Score
How does Repligen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Repligen's score of 34 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Repligen's reported carbon emissions
In 2023, Repligen Corporation reported total carbon emissions of approximately 15,000,000 kg CO2e, comprising 2,236,000 kg CO2e from Scope 1, 959,000 kg CO2e from Scope 2, and about 14,940,000 kg CO2e from Scope 3 emissions. This marked a significant increase from previous years, with total emissions recorded at 16,377,000 kg CO2e in 2022, 3,960,000 kg CO2e in 2021, and 3,250,000 kg CO2e in 2020. Repligen has committed to achieving net-zero emissions by 2050, as part of its long-term climate strategy. This commitment encompasses all scopes of emissions, aligning with the Science Based Targets initiative (SBTi). The company has been proactive in its climate commitments, having established a near-term target status of "Committed" as of February 2024. The company’s emissions intensity has shown variability, with a notable increase in emissions correlating with revenue growth, which reached approximately USD 632 million in 2023. Repligen's ongoing efforts to reduce its carbon footprint reflect its dedication to sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 517,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 2,219,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 |
| Scope 3 | - | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Repligen is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
